Women with posttraumatic stress disorder (PTSD) who abused drugs responded better to substance abuse treatment after their PTSD symptoms improved, according to a recent study, which also found that reductions in substance abuse did not ease PTSD severity
April 2012 Dr. Volkow discusses NIDA’s efforts to develop effective antismoking treatments for populations with persistently high rates of smoking, such as people with psychiatric disorders, high school dropouts, and Native Americans.
July 2012 Dr. J. David Jentsch is the recipient of the 2011 Jacob P. Waletzky Memorial Award for Innovative Research in Drug Addiction and Alcoholism. Dr. Jentsch and colleagues at the University of California, Los Angeles, are studying genetic and neurochemical factors that influence individual differences in inhibitory control.
Sublingual buprenorphine is a safe and effective alternative to methadone for treating opioid dependence during pregnancy, finds the Maternal Opioid Treatment: Human Experimental Research (MOTHER) study, a NIDA-supported clinical trial. Women who received either medication had similar pregnancy and birth outcomes, but infants born to women who received buprenorphine had milder symptoms of neonatal opioid withdrawal.
Soluble-film preparations of buprenorphine suppressed heroin abusers’ withdrawal symptoms with no serious side effects in a recent clinical trial. They dissolved more rapidly in the mouth than the pill form of the medication, providing faster relief.
NIDA researchers have developed a computer program that motivates and encourages treatment-seeking when an individual is in a primary care physician’s waiting room. Users of the program, called Video Doctor, enter information on a portable device and receive feedback about health risks related to their drug abuse, along with advice, immediately prior to seeing their physician.